[Myopathy and zidovudine] NLM AIDSLINE Important note: Information in this article was accurate in 1993. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


[Myopathy and zidovudine]

Enferm Infecc Microbiol Clin. 1992 Oct;10(8):474-6. Unique Identifier : AIDSLINE MED/93144377
Mateo O; Gato A; Ballesteros P; Benito L; Pontes MJ; Esquinas G; Servicio de Medicina Interna, Hospital Universitario de Getafe,; Madrid.

Abstract: BACKGROUND: The aim of this study was to evaluate the frequency of appearance of myopathy in a group of patients treated with zidovudine. METHODS: A prospective study of 37 patients with positive serology for HIV treated over 180 days with zidovudine was carried out with evaluation of the clinical history, physical examination and analytical data. RESULTS: The initial mean value of creatine kinase of 76.4 U/l and 83.3 U/l following 6 months of treatment was not statistically significant. Of the 37 patients, 2 (5.4%) showed no variations in CK values, while in 4 (10.8%) there was a decrease and in 30 (81%) an increase. There was an elevation in 11 of the 15 patients (73%) who received doses equal to or lower than 90 g, 11 out of 13 (84.6%) of those who received between 90 and 145 g and 8 out of 8 (100%) of those having received doses higher than 145 g. This increase was minimum in 27 cases (92%) and important with final values of pathologic CK in 3 (8%). Two patients (5.4%) developed clinical manifestations. CONCLUSIONS: Not only the frequency and range of creatine kinase elevation but also the appearance of clinical manifestations in this study are lower than those found in the literature, probably because of the relation with the use of lower doses of zidovudine. These results do not demonstrate any relation with sex, age, risk group for the immunodeficiency status.
Keywords: Acquired Immunodeficiency Syndrome/BLOOD/DRUG THERAPY Adult Biological Markers Blood Glucose/ANALYSIS/DRUG EFFECTS Blood Proteins/ANALYSIS Comparative Study Creatine Kinase Isoenzymes/*BLOOD Dose-Response Relationship, Drug English Abstract Female Human Leukocyte Count/DRUG EFFECTS Male Middle Age Muscular Diseases/BLOOD/*CHEMICALLY INDUCED/ENZYMOLOGY Prospective Studies Risk Factors Urea/BLOOD Zidovudine/ADMINISTRATION & DOSAGE/*ADVERSE EFFECTS/THERAPEUTIC USE JOURNAL ARTICLEKWDacquiredimmunodeficiencysyndrome/blood/drugtherapyadultbiologicalmarkersbloodglucose/analysis/drugeffectsbloodproteins/analysiscomparativestudycreatinekinaseisoenzymes/KWDblooddose-responserelationship,drugenglishabstractfemalehumanleukocytecount/drugeffectsmalemiddleagemusculardiseases/blood/KWDchemicallyinduced/enzymologyprospectivestudiesriskfactorsurea/bloodzidovudine/administration&dosage/KWDadverseeffects/therapeuticusejournalarticle
930530
M9350955

Copyright © 1993 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1993. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1993. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .